The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic
target in patients with breast or gastric cancer selected on the basis of HER2 overexpression …

Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of
cancer-related death. The mainstay of treatment for metastatic colorectal cancer is …

Colorectal cancer (CRC) is one of the most common malignancies, accounting for
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …

Background Trastuzumab deruxtecan has shown encouraging activity in patients with
treatment-refractory HER2-positive, RAS wild-type and BRAF wild-type metastatic colorectal …

Background DESTINY-Lung01 is a multicentre, open-label, phase 2 study evaluating the
antitumour activity and safety of trastuzumab deruxtecan, a HER2-directed antibody-drug …

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second
leading cause of cancer death in the United States. Management of disseminated metastatic …

Therapeutic developments in the targeting of human epidermal growth factor receptor 2
(HER2)-expressing gastric cancer have followed the dramatic success of HER2-expressing …

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2-
positive malignancies across various tumor types. Through its unique composition, T-DXd …

The last two decades have witnessed major breakthroughs in the development of targeted
therapy for patients with metastatic colorectal cancer (mCRC), an achievement which stems …

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths
worldwide. The 5-year survival rate after curative resection is almost 80%, however, it is still …